Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi

G Harth1, N Andrews, A A Mills

  • 1Palo Alto Medical Foundation, CA.

Insights

Inhibiting a key cysteine protease in Trypanosoma cruzi, the parasite causing Chagas' disease, halts its replication and transformation. This T. cruzi enzyme is a promising drug target with minimal host cell toxicity.

Area of Science:

  • Parasitology
  • Molecular Biology
  • Drug Discovery

Background:

  • Trypanosoma cruzi possesses a major cysteine protease essential for its life cycle.
  • This protease is a potential target for developing new Chagas' disease therapies.

Purpose of the Study:

  • To investigate the function of the T. cruzi cysteine protease.
  • To evaluate cysteine protease inhibitors as potential drug leads for Chagas' disease.

Main Methods:

  • Utilized two fluoromethyl ketone-derivatized cysteine protease inhibitors.
  • Assessed inhibitor effects on T. cruzi infection and replication in mammalian cells.

Main Results:

  • Inhibitors arrested parasite replication, particularly during stage transformations.
  • Effective concentrations showed no observable toxicity to host cells (macrophages, fibroblasts, epithelial cells).

Conclusions:

  • The T. cruzi cysteine protease is involved in intracellular protein degradation and stage remodeling.
  • Targeting this protease offers a potential therapeutic strategy for Chagas' disease with a favorable safety profile.

Related Concept Videos

American Trypanosomiasis01:22

American Trypanosomiasis

Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...